Servier is pleased to announce a strategic partnership with Black Diamond Therapeutics and the establishment of a worldwide licensing agreement for BDTX-4933. This small molecule targeted therapy is designed to potentially address the needs of patients with solid tumors harboring RAS and RAF mutations. https://lnkd.in/eh8a2rcW
关于我们
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- 网站
-
https://www.servier.us/
Servier Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Boston ，MA
- 类型
- 非营利机构
地点
-
主要
获取路线
200 Pier Four Boulevard
US，MA ，Boston ，02210
Servier Pharmaceuticals员工
动态
-
This month Servier and LabCentral will be holding the pitch event for Golden Ticket Contest Finalists. Leading up to the event we’ll be highlighting the finalists who are competing to win premier shared lab space and services as well as access to Servier’s team of experts. Today’s spotlight is on Apeture Bio.
-
-
When it comes to a #glioma diagnosis, knowledge is powerful. Servier emphasizes the importance of mutational testing as a critical step in the process, and for #healthcare providers to discuss the latest findings in mutational status with patients, as they develop a personalized treatment plan. Learn more about Servier's approach: https://lnkd.in/ezjCdRWB
-
-
The future of #STEM is bright! Servier’s Vice President, Global Head of Oncology Late Stage Clinical Development, Susan Pandya, M.D., recently volunteered as a judge for the Boston Public Schools STEM Fair, where she reviewed projects from talented middle and high school students across science, engineering, computer science, and mathematics. ? We are inspired by the passion and creativity of the next generation of STEM leaders in #Boston and proud of leaders, like Susan, who give back to our communities whenever possible.
Vice President, Clinical Development and Global Head of Oncology LS/LCM | Former Clinician | Developing Novel Oncology Therapies for Patients
On this crisp but sunny Boston Saturday morning, I had the pleasure to serve as a judge at the BPS STEM Fair for middle and high school students! Boston is a city built on innovation, and it was great to see a glimpse into what the next generation of innovators has in store for us. I had the opportunity to see students from Boston Public Schools showcase their creativity, research projects, problem-solving skills, and passion for STEM. They’re asking big questions, testing ideas, and thinking like real scientists and engineers. I can say with confidence that Boston’s STEM future is bright! ?? But it takes all of us—educators, industry leaders, and mentors—to create pathways for the next generation. Huge thanks to Boston Public Schools and the Center for STEM Education for hosting such an inspiring event. If you’ve ever considered getting involved in a STEM fair or mentorship program—do it! These students are the future. And they’re already making an impact. #STEM #boston #stemfair #womeninscience #innovation #internationalwomensday
-
-
In honor of #InternationalWomensDay, Servier hosted a roundtable event “Breaking barriers: driving equity in science and tech firms,” where Servier Pharmaceuticals leaders participated in meaningful panel discussions on gender equity in science - highlighting inspiring success stories and sharing actionable strategies for change. #ICYMI, access the full panels here: https://lnkd.in/dFnan-3F
Women in science: fostering innovation in tech and science companies!
https://www.youtube.com/
-
At Servier, we believe in cultivating a people-first culture that recognizes the incredible contributions our teams make each day. Hear from our CEO, David K. Lee, about what building this means to him. #EmployeeAppreciationDay
Today, on Employee Appreciation Day, I want to take a moment to thank each and every employee at Servier Pharmaceuticals.? ? Your dedication, passion, and relentless pursuit of innovation make Servier what it is. ? Because of you… ? >> We push boundaries—exploring new science, new partnerships, and new possibilities. >> We move fast—making critical decisions purposefully. >> We commit fully—challenging each other and striving for excellence in everything we do. ? The work you do matters.?Thank you for your unwavering commitment to our mission.? ? #employeeappreciation #employeeappreciationday #pharma #innovation #servier ? ?
-
-
Last week, Servier Pharmaceuticals joined thousands of #lifescience leaders at the local, state and federal level to honor #RareDiseaseDay and discuss the latest advancements in #raredisease research. We are moved by the stories and experiences of #patients and caregivers impacted by rare diseases, and we continue to work to help drive progress for this community.
-
-
As a proud sponsor of the California Life Sciences (CLS) FAST Advisory Program, each year we provide founders of disruptive innovative life science companies with a customized advisory program to perfect their business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit. ? This year, we supported Cenos Therapeutics, a company pioneering the future of neurological health through innovative RNA therapeutics, who last month shared their business plan with other participants of the FAST Advisory Program. Congratulations to Cenos! ? Click here to learn more about the program – https://lnkd.in/g3mWqMxx
-
-
Building on our research presented at ASH 2024, we are excited to announce that the first patient has been treated with our novel, first-in-class CD74-directed ADC with an MCL-1 inhibitor payload in our global Phase 1 clinical trial (NCT06563804). https://lnkd.in/ecwC5dq4
-
-
Last week, Jeff Knipstein, Medical Director, Oncology Therapeutic Area, LS/LCM at Servier, participated in the Glioblastoma Drug Development Summit in Boston. Learn more about the conference and Jeff’s presentation –
For the past six years, the Glioblastoma Drug Development Summit has provided a space for those in our industry to share experiences, dive into learning processes and give an opportunity to collaborate with other experts in the field. This year, I was able to share a summary of our research to-date in IDH-mutant glioma and provide a window into what’s next for Servier in this space. ? Thank you to all who attended the session and to all those at the summit aiming to advance treatments for patients! ? https://lnkd.in/ef6MAzWf
-